Academic journal article Journal of Visual Impairment & Blindness

Drugs to Treat Age-Related Macular Degeneration Compared in Trial

Academic journal article Journal of Visual Impairment & Blindness

Drugs to Treat Age-Related Macular Degeneration Compared in Trial

Article excerpt

In late February 2008, the National Institutes of Health (NIH) initiated a head-to-head trial of two Genentech drugs designed to treat the wet form of age-related macular degeneration (AMD), which occurs when abnormal blood vessel growth harms or destroys part of the eye. The trial will pit Lucentis, which was approved in 2006 to treat wet AMD, against a chemically similar drug, Avastin, which was approved in 2004 to treat cancer. Both drugs are designed to inhibit a protein needed in blood vessel formation, thus preventing the growth of harmful blood vessels, and both drugs will be administered by single monthly injections into the eyes. The study, funded by the National Eye Institute (NEI), will involve 1,200 patients who will receive a monthly dose of either Lucentis or Avastin during an initial one-year treatment period. Patients will then be divided into additional treatment groups for the second year of the trial and will be treated with either drug on a varying schedule. The study will measure changes in vision after treatment with the two drugs and will also look at the number of treatments, anatomical changes in the retina, adverse events, and cost. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.